Established in 1997, Prana Biotechnology is a world leader in addressing the role of biological metals in human disease. Abundant scientific evidence suggests that many age-related conditions result from pathological interactions between selected metals and target proteins. The company has developed a proprietary library of chemical compounds that target these interactions, preventing protein aggregation and corruption. The mission of the company is to develop disease modifying therapeutics for the treatment of common neurological disorders, with a focus upon Alzheimer's, Parkinson's and Huntington's diseases. Other potential applications for this platform technology include specific cancers and Age-related Macular Degeneration.

Latest News 9 May 2012 Dr Rudy Tanzi to Discuss PBT2 Trial on Thursday, May 10      Learn more 1 May 2012 MGH team publishes data that supports the use of Prana's PBT2 in Huntington Disease       Learn more 30 April 2012 Prana Enrolls First Patient in the "Reach2HD" Phase II Huntington Disease Trial       Learn more 26 March 2012 PLoS ONE Journal Publishes Mechanistic Model of Alzheimer's Disease Endorsing Prana's PBT2       Learn more 6 March 2012 Prana Doses First Patient in the IMAGINE PhII Alzheimer's Disease Trial       Learn more  2 February 2012 Prana Comments on Articles that Highlight the Role of Metals in Neurodegenerative Diseases       Learn more 11 January 2012 Professor Tanzi Appointed Prana's Chief Scientific Advisor      Learn more     PBT2 Therapeutic Strategy Statement Subscribe / E-mail alerts